28355982|t|Low copy numbers of FCGR3A and FCGR3B associated with Chinese patients with SLE and AASV
28355982|a|Low-affinity Fcγ receptors (FcγR) act as key mediators of the pathogenic effects of autoantibodies. In this study, we aimed to determine whether copy number variations (CNVs) in FCGR3A and FCGR3B were associated with systemic lupus nephritis (SLE) and ANCA-associated systemic vasculitis (AASV) in Chinese individuals. A total of 1118 individuals were enrolled, including 415 SLE patients, 139 AASV patients, and 564 healthy controls. FCGR3A and FCGR3B copy numbers (CNs) were determined by both a paralogue ratio test and TaqMan quantitative PCR assay. In the susceptibility associations, a low FCGR3B CN was significantly associated with SLE (p = 5.01 × 10(-3); odds ratio (OR) 1.71; 95% confidence interval (CI) 1.17-2.48) and AASV (p = 0.04; OR = 1.72; 95% CI 1.02-2.88). A low FCGR3A CN was also significantly associated with SLE (p = 6.02 × 10(-3); OR 2.72; 95% CI 1.30-5.71) and AASV (p = 0.042; OR 2.64; 95% CI 1.00-6.93). Further subphenotype analysis revealed that low CNs of FCGR3A and FCGR3B were significantly associated with clinical manifestations in SLE and AASV patients. Therefore, in this case-control study, we identified low CNs of FCGR2A and FCGR3B to be common risk factors for SLE and AASV.
28355982	0	3	Low	T081	C1611820
28355982	4	16	copy numbers	T081	C0178655
28355982	20	26	FCGR3A	T028	C1414555
28355982	31	37	FCGR3B	T028	C1414556
28355982	38	53	associated with	T080	C0332281
28355982	54	61	Chinese	T098	C0152035
28355982	62	70	patients	T101	C0030705
28355982	76	79	SLE	T047	C0024143
28355982	84	88	AASV	T047	C2717865
28355982	89	115	Low-affinity Fcγ receptors	T116,T129,T192	C0162826
28355982	117	121	FcγR	T116,T129,T192	C0162826
28355982	151	161	pathogenic	T169	C0543483
28355982	162	169	effects	T080	C1280500
28355982	173	187	autoantibodies	T116,T129	C0004358
28355982	197	202	study	T062	C0008972
28355982	234	256	copy number variations	T045	C2717925
28355982	258	262	CNVs	T045	C2717925
28355982	267	273	FCGR3A	T028	C1414555
28355982	278	284	FCGR3B	T028	C1414556
28355982	290	305	associated with	T080	C0332281
28355982	306	330	systemic lupus nephritis	T047	C0024143
28355982	332	335	SLE	T047	C0024143
28355982	341	376	ANCA-associated systemic vasculitis	T047	C2717865
28355982	378	382	AASV	T047	C2717865
28355982	387	406	Chinese individuals	T098	C0152035
28355982	424	435	individuals	T098	C0027361
28355982	441	449	enrolled	T058	C1516879
28355982	465	468	SLE	T047	C0024143
28355982	469	477	patients	T101	C0030705
28355982	483	487	AASV	T047	C2717865
28355982	488	496	patients	T101	C0030705
28355982	506	522	healthy controls	T080	C2986479
28355982	524	530	FCGR3A	T028	C1414555
28355982	535	541	FCGR3B	T028	C1414556
28355982	542	554	copy numbers	T081	C0178655
28355982	556	559	CNs	T081	C0178655
28355982	566	576	determined	T080	C0521095
28355982	587	607	paralogue ratio test	T059	C0022885
28355982	612	641	TaqMan quantitative PCR assay	T059	C0200931
28355982	650	664	susceptibility	T201	C0012655
28355982	665	677	associations	T080	C0439849
28355982	681	684	low	T081	C1611820
28355982	685	691	FCGR3B	T028	C1414556
28355982	692	694	CN	T081	C0178655
28355982	713	728	associated with	T080	C0332281
28355982	729	732	SLE	T047	C0024143
28355982	753	763	odds ratio	T081	C0028873
28355982	765	767	OR	T081	C0028873
28355982	779	798	confidence interval	T081	C0009667
28355982	800	802	CI	T081	C0009667
28355982	819	823	AASV	T047	C2717865
28355982	835	837	OR	T081	C0028873
28355982	850	852	CI	T081	C0009667
28355982	867	870	low	T081	C1611820
28355982	871	877	FCGR3A	T028	C1414555
28355982	878	880	CN	T081	C0178655
28355982	904	919	associated with	T080	C0332281
28355982	920	923	SLE	T047	C0024143
28355982	944	946	OR	T081	C0028873
28355982	957	959	CI	T081	C0009667
28355982	975	979	AASV	T047	C2717865
28355982	992	994	OR	T081	C0028873
28355982	1005	1007	CI	T081	C0009667
28355982	1028	1040	subphenotype	T032	C0031437
28355982	1041	1049	analysis	T062	C0936012
28355982	1050	1058	revealed	T080	C0443289
28355982	1064	1067	low	T081	C1611820
28355982	1068	1071	CNs	T081	C0178655
28355982	1075	1081	FCGR3A	T028	C1414555
28355982	1086	1092	FCGR3B	T028	C1414556
28355982	1112	1127	associated with	T080	C0332281
28355982	1155	1158	SLE	T047	C0024143
28355982	1163	1167	AASV	T047	C2717865
28355982	1168	1176	patients	T101	C0030705
28355982	1197	1215	case-control study	T062	C0007328
28355982	1220	1230	identified	T080	C0205396
28355982	1231	1234	low	T081	C1611820
28355982	1235	1238	CNs	T081	C0178655
28355982	1242	1248	FCGR2A	T028	C1414553
28355982	1253	1259	FCGR3B	T028	C1414556
28355982	1273	1285	risk factors	T033	C0035648
28355982	1290	1293	SLE	T047	C0024143
28355982	1298	1302	AASV	T047	C2717865